ArticleJournal of nanobiotechnology2026
Poria cocos-derived exosome-like nanoparticles ameliorate lymphedema by reprogramming fibroblast metabolism via enhanced TCA cycle flux.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Lymphedema is a chronic condition characterized by impaired lymphatic drainage, leading to tissue fibrosis and functional impairment, with no effective pharmacological treatments currently available. This study investigated the therapeutic potential of Plant-Derived Exosome-like Nanoparticles (PELNs), particularly those from Poria cocos-Derived Exosome-like Nanoparticles (PcELNs), in treating lymphedema. We isolated PELNs from five botanical sources and found that PcELNs exhibited superior efficacy in alleviating lymphedema symptoms in a mouse model. Multi-omics analyses (transcriptomic, proteomic, metabolomic) revealed that PcELNs induce metabolic reprogramming in human foreskin fibroblasts (HFFs), shifting cell metabolism from glycolysis towards mitochondrial oxidative phosphorylation. This shift may be mediated through enhancing amino acid metabolism and TCA cycle flux, ultimately increasing oxidative phosphorylation. Furthermore, PcELNs reversed TGF-β-induced pro-fibrotic activation, promoting a matrix-remodeling phenotype. In vivo, PcELNs significantly ameliorated lymphedema by upregulating matrix metalloproteinases (MMP1a, MMP3) and improving mitochondrial function. Our findings demonstrate that PcELNs represent a novel and effective nanotherapeutic strategy for lymphedema by orchestrating metabolic reprogramming and inhibiting fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.